Top

Published in:

01-03-2013 | Review Article

Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease

Authors: Chan Wah-Kheong, Goh Khean-Lee

Published in: Hepatology International | Issue 1/2013

Abstract

Non-alcoholic fatty liver disease (NAFLD) is rapidly increasing in the Asia-Pacific and affects up to 30 % of the general population. In younger children, prevalence has been reported to be between 2.1 and 4.5 %. The prevalence of NAFLD increases with increasing age. NAFLD is more prevalent in men than women, but this trend fades in older age group. NAFLD is one of the most common causes of raised serum ALT levels and the latter is closely related to the presence of features of metabolic syndrome. NAFLD may contribute to metabolic syndrome in a similar way as visceral adiposity and can be an early predictor of metabolic disorders. NAFLD increases the risk of developing diabetes mellitus and is closely related to degree of glucose intolerance. A significant proportion of patients with NAFLD have impaired glucose tolerance or diabetes mellitus but with normal fasting blood glucose, highlighting the importance of oral glucose tolerance test in NAFLD patients with normal fasting blood glucose. Besides liver-related complications, NAFLD has been associated with cardiovascular complications, hyperuricemia, gout, chronic kidney disease, gallstone disease, colorectal adenomatous polyp, and polycystic ovarian syndrome. NAFLD seems to be related to host metabolic factors rather than viral factors and does not seem to affect severity of the liver disease in patients with chronic hepatitis B. On the other hand, hepatic steatosis may be related to both host metabolic and viral factors in patients with chronic hepatitis C and seems to adversely impact on the severity of liver disease and possibly response to antiviral therapy.

Hou XH, Zhu YX, Lu HJ, et al. Non-alcoholic fatty liver disease’s prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol 2011;26:722–730PubMedCrossRef

Gao AB, Xiao Q, Li LY, et al. Epidemiological survey of the association between non alcoholic fatty liver disease and metabolic syndrome in civil servants of Chongqing city. Zhonghua Yu Fang Yi Xue Za Zhi 2008;42:107–110PubMed

Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007;13:6419–6424PubMedCrossRef

Chen ZW, Chen LY, Dai HL, et al. Relationship between alanine aminotransferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008;9:616–622PubMedCrossRef

Li Y, Xu C, Yu C, et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 2009;50:1029–1034PubMedCrossRef

Li H, Wang YJ, Tan K, et al. Prevalence and risk factors of fatty liver disease in Chengdu, Southwest China. Hepatobiliary Pancreat Dis Int 2009;8:377–382PubMed

Kang WM, Zhang JS, Wang MS, et al. Prevalence of metabolic syndrome and its associations with other metabolic disorders and cardiovascular changes in health examination population in Beijing. Chin Med Sci J 2009;24:227–230PubMedCrossRef

Dai H, Chu L, Song S, et al. Prevalence of and risk factors for fatty liver disease in a professional population of Wuhan, China. Public Health 2009;123:545–548PubMedCrossRef

Fan JG, Zhu J, Li XJ, et al. Fatty liver and the metabolic syndrome among Shanghai adults. J Gastroenterol Hepatol 2005;20:1825–1832PubMedCrossRef

10.

Fan JG, Li F, Cai XB, et al. The importance of metabolic factors for the increasing prevalence of fatty liver in Shanghai factory workers. J Gastroenterol Hepatol 2007;22:663–668PubMedCrossRef

11.

Wang Z, Xia B, Ma C, et al. Prevalence and risk factors of fatty liver disease in the Shuiguohu district of Wuhan city, central China. Postgrad Med J 2007;83:192–195PubMedCrossRef

12.

Oya J, Nakagami T, Sasaki S, et al. Intake of n-3 polyunsaturated fatty acids and non-alcoholic fatty liver disease: a cross-sectional study in Japanese men and women. Eur J Clin Nutr 2010;64:1179–1185PubMedCrossRef

13.

Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141–1145PubMedCrossRef

14.

Saito Y, Yagyu K, Hattori Y, et al. A study on fatty liver in health examination participants. Nihon Eiseigaku Zasshi 1989;44:953–961PubMedCrossRef

15.

Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003;38:954–961PubMedCrossRef

16.

Akahoshi M, Amasaki Y, Soda M, et al. Correlation between fatty liver and coronary risk factors: a population study of elderly men and women in Nagasaki, Japan. Hypertens Res 2001;24:337–343PubMedCrossRef

17.

Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 2006;21:138–143PubMedCrossRef

18.

Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389–2395PubMedCrossRef

19.

Kim HJ, Lee KE, Kim DJ, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169–2175PubMedCrossRef

20.

Kuo CF, Yu KH, Luo SF, et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol 2010;39:466–471PubMedCrossRef

21.

Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol 2006;40:745–752PubMedCrossRef

22.

Tsai CH, Li TC, Lin CC. Metabolic syndrome as a risk factor for nonalcoholic fatty liver disease. South Med J 2008;101:900–905PubMedCrossRef

23.

Hsiao PJ, Kuo KK, Shin SJ, et al. Significant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol 2007;22:2118–2123PubMedCrossRef

24.

Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005;11:4838–4842PubMed

25.

Lai SW, Tan CK, Ng KC. Epidemiology of fatty liver in a hospital-based study in Taiwan. South Med J 2002;95:1288–1292PubMed

26.

Lu SN, Wang LY, Chang WY, et al. Abdominal sonographic screening in a single community. Gaoxiong Yi Xue Ke Xue Za Zhi 1990;6:643–646PubMed

27.

Amarapurkar D, Kamani P, Patel N, et al. Prevalence of non-alcoholic fatty liver disease: population based study. Ann Hepatol 2007;6:161–163PubMed

28.

Mohan V, Farooq S, Deepa M, et al. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. Diabetes Res Clin Pract 2009;84:84–91PubMedCrossRef

29.

Singh SP, Nayak S, Swain M, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 2004;25:76–79PubMed

30.

Das K, Mukherjee PS, Ghosh A, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593–1602PubMedCrossRef

31.

Dassanayake AS, Kasturiratne A, Rajindrajith S, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009;24:1284–1288PubMedCrossRef

32.

Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, et al. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006;26:856–863PubMedCrossRef

33.

Rungsinaporn K, Phaisakamas T. Frequency of abnormalities detected by upper abdominal ultrasound. J Med Assoc Thai 2008;91:1072–1075PubMed

34.

Goh SC, Ho E, Goh KL (2012) Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hepatology International 2012, published online

35.

Caballeria L, Pera G, Auladell MA, et al. Prevalence and factors associated with the presence of nonalcoholic fatty liver disease in an adult population in Spain. Eur J Gastroenterol Hepatol 2010;22:24–32PubMedCrossRef

36.

Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44–52PubMedCrossRef

37.

Wan YP, Xu RY, Fang H, et al. The prevalence of non-alcoholic fatty liver disease and its related risk factors in 1180 school children in Shanghai. Zhonghua Gan Zang Bing Za Zhi 2007;15:644–648PubMed

38.

Tsuruta G, Tanaka N, Hongo M, et al. Nonalcoholic fatty liver disease in Japanese junior high school students: its prevalence and relationship to lifestyle habits. J Gastroenterol 2010;45:666–672PubMedCrossRef

39.

Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002–2009PubMedCrossRef

40.

Alavian SM, Mohammad-Alizadeh AH, Esna-Ashari F, et al. Non-alcoholic fatty liver disease prevalence among school-aged children and adolescents in Iran and its association with biochemical and anthropometric measures. Liver Int 2009;29:159–163PubMedCrossRef

41.

Adibi A, Kelishadi R, Beihaghi A, et al. Sonographic fatty liver in overweight and obese children, a cross sectional study in Isfahan. Endokrynol Pol 2009;60:14–19PubMed

42.

Shi HB, Fu JF, Liang L, et al. Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children. Zhonghua Er Ke Za Zhi 2009;47:114–118PubMed

43.

Fu JF, Liang L, Wang CL, et al. Nonalcoholic steatohepatitis in obese children: the prevalence and possible mechanism. Zhejiang Da Xue Xue Bao Yi Xue Ban 2006;35:64–68PubMed

44.

Sagi R, Reif S, Neuman G, et al. Nonalcoholic fatty liver disease in overweight children and adolescents. Acta Paediatr 2007;96:1209–1213PubMedCrossRef

45.

Fang JG, Zhu J, Li XJ, et al. Epidemiological survey of prevalence of fatty liver and its risk factors in a general adult population of Shanghai. Zhonghua Gan Zang Bing Za Zhi 2005;13:83–88PubMed

46.

Ayonrinde OT, Olynyk JK, Beilin LJ, et al. Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011;53:800–809PubMedCrossRef

47.

Chen CH, Huang MH, Yang JC, et al. Prevalence and etiology of elevated serum alanine aminotransferase level in an adult population in Taiwan. J Gastroenterol Hepatol 2007;22:1482–1489PubMedCrossRef

48.

Jamali R, Khonsari M, Merat S, et al. Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol 2008;14:2867–2871PubMedCrossRef

49.

Yamada T, Fukatsu M, Suzuki S, et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352–356PubMedCrossRef

50.

Shibata M, Kihara Y, Taguchi M, et al. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 2007;30:2940–2944PubMedCrossRef

51.

Agarwal AK, Jain V, Singla S, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India 2011;59:351–354PubMed

52.

Zhou J, Jia WP, Bao YQ, et al. Study on prevalence and risk factors of fatty liver of patients with type 2 diabetes. Zhonghua Yi Xue Za Zhi 2007;87:2249–2252PubMed

53.

Wong VW, Hui AY, Tsang SW, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;24:1215–1222PubMedCrossRef

54.

Assy N, Djibre A, Farah R, et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010;254:393–400PubMedCrossRef

55.

Fotbolcu H, Yakar T, Duman D, et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 2010;17:457–463PubMed

56.

Aygun C, Kocaman O, Sahin T, et al. Evaluation of metabolic syndrome frequency and carotid artery intima-media thickness as risk factors for atherosclerosis in patients with nonalcoholic fatty liver disease. Dig Dis Sci 2008;53:1352–1357PubMedCrossRef

57.

Yasui K, Sumida Y, Mori Y, et al. Nonalcoholic steatohepatitis and increased risk of chronic kidney disease. Metabolism 2011;60:735–739PubMedCrossRef

58.

Chen CH, Huang MH, Yang JC, et al. Prevalence and risk factors of gallstone disease in an adult population of Taiwan: an epidemiological survey. J Gastroenterol Hepatol 2006;21:1737–1743PubMedCrossRef

59.

Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol 2010;25:562–567PubMedCrossRef

60.

Brzozowska MM, Ostapowicz G, Weltman MD. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol 2009;24:243–247PubMedCrossRef

61.

Shi JP, Fan JG, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008;23:1419–1425PubMedCrossRef

62.

Yun JW, Cho YK, Park JH, et al. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int 2009;29:878–883PubMedCrossRef

63.

Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001;16:190–195PubMedCrossRef

64.

Liu CJ, Jeng YM, Chen PJ, et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 2005;10:405–415PubMed

65.

Ahmed AM, Hassan MS, Abd-Elsayed A, et al. Insulin resistance, steatosis, and fibrosis in Egyptian patients with chronic Hepatitis C virus infection. Saudi J Gastroenterol 2011;17:245–251PubMedCrossRef

66.

Minakari M, Sameni FK, Shalmani HM, et al. Hepatic steatosis in Iranian patients with chronic hepatitis C. Med Princ Pract 2008;17:126–130PubMedCrossRef

Title: Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease
Authors: Chan Wah-Kheong
Goh Khean-Lee
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Hepatology International / Issue 1/2013
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-012-9384-1

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Epidemiology of a fast emerging disease in the Asia-Pacific region: non-alcoholic fatty liver disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Hepatic angiogenesis and fibrosis are common features in morbidly obese patients

Early primary prophylaxis with beta-blockers does not prevent the growth of small esophageal varices in cirrhosis: a randomized controlled trial

Short hairpin RNAs with a 2- or 3-base mismatch inhibit HBV expression and replication in HepG2 cells

Angiogenesis: a phenomenon which aggravates chronic liver disease progression

Comparative proteomic analysis of human donor tissues during orthotopic liver transplantation: ischemia versus reperfusion

Hepatitis C infection and chronic renal diseases

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page